ESC 365
Menu
Home
Search
Live & Upcoming Events
About
Create an account
Sign in
Back
ESC Premium Access
Controversies in antithrombotic treatment for primary and secondary prevention
Event:
ESC CONGRESS 2019
Topic:
Cardiovascular Pharmacotherapy
Session type:
Debate Session
Date:
3 September 2019
Time:
11:00 - 12:30
Session
0
6
presentations
in this session
Aspirin is out for primary prevention of cardiovascular disease - PRO.
Speaker:
Professor J. Armitage (Oxford, GB)
Access
Slides
Video
0
Aspirin is out for primary prevention of cardiovascular disease - CON.
Speaker:
Professor C. Patrono (Rome, IT)
Access
Slides
Video
0
Aspirin is out for primary prevention of cardiovascular disease - Discussion.
Access
Video
0
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.
Speaker:
Doctor J. Eikelboom (Hamilton, CA)
Access
Slides
Video
0
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - CON.
Speaker:
Doctor T. Cuisset (Marseille, FR)
Access
Slides
Video
0
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - Discussion.
Access
Video
0
4
speakers
from this session
Professor Jane Armitage
University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
10
presentations
1
follower
Professor Carlo Patrono
Catholic University of the Sacred Heart, Rome (Italy)
4
presentations
0
follower
Doctor John William Eikelboom
McMaster University, Hamilton (Canada)
32
presentations
0
follower
Doctor Thomas Cuisset
AP-HM - Hospital La Timone, Marseille (France)
4
presentations
0
follower
This platform is supported by